Corbus Pharmaceuticals Holdings Inc
CRBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$121.34M
Close$
$2.02
77.7% downside
Current Fair Value
77.7% downsideOvervalued by 77.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $121.34 Million |
|---|---|
| Enterprise Value | $96.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.9 |
| Beta | 2.56 |
| Outstanding Shares | 13,317,116 |
Return
| Return on Equity | -66.90% |
|---|---|
| Return on Assets | -58.50% |
| Return on Invested Capital | 9.51% |
Valuation & Multiples
| P/E Ratio | -1.47 |
|---|---|
| PEG | -4.16 |
| Price to Sales | - |
| Price to Book Ratio | 1.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 8.03 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-1.26
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-1.30
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Corbus Pharmaceuticals Holdings, Inc.
28 employees
CEO: Dr. Yuval Cohen Ph.D. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid...